Document:

2008 Employee Stock Purchase Plan

 EXHIBIT 10.3 
 PHENOMIX CORPORATION 
 2008 EMPLOYEE STOCK PURCHASE PLAN 
 The purpose of the Phenomix Corporation 2008 Employee Stock Purchase Plan (the “Plan”) is to provide eligible employees of
Phenomix Corporation (the “Company”) and each Designated Subsidiary (as defined in Section 11) with opportunities to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common
Stock”).             shares of Common Stock in the aggregate have been approved and reserved for this purpose. The Plan is intended to constitute an “employee stock
purchase plan” within the meaning of Section 423(b) of the Internal Revenue Code of 1986, as amended (the “Code”), and shall be interpreted in accordance with that intent. 
 1. Administration. The Plan will be administered by the person or persons (the “Administrator”) appointed by the
Company’s Board of Directors (the “Board”) for such purpose. The Administrator has authority at any time to: (i) adopt, alter and repeal such rules, guidelines and practices for the administration of the Plan and
for its own acts and proceedings as it shall deem advisable; (ii) interpret the terms and provisions of the Plan; (iii) make all determinations it deems advisable for the administration of the Plan; (iv) decide all disputes arising in
connection with the Plan; and (v) otherwise supervise the administration of the Plan. All interpretations and decisions of the Administrator shall be binding on all persons, including the Company and the Participants. No member of the Board or
individual exercising administrative authority with respect to the Plan shall be liable for any action or determination made in good faith with respect to the Plan or any option granted hereunder. 

 2. Offerings. The Company will make one or more offerings to eligible employees to purchase Common
Stock under the Plan (“Offerings”). Unless otherwise determined by the Administrator, the initial Offering will begin on the first day of the Company’s Initial Public Offering and will end on the following
December 31 (the “Initial Offering”). Thereafter, unless otherwise determined by the Administrator, an Offering will begin on the first business day occurring on or after each January 1 and will end on the last
business day occurring on or before the following December 31. The Administrator may, in its discretion, designate a different period for any Offering, provided that no Offering shall exceed 27 months in duration or overlap any other Offering.

 3. Eligibility. All individuals classified as employees on the payroll records of the Company and each Designated Subsidiary are
eligible to participate in any one or more of the Offerings under the Plan, provided that as of the first day of the applicable Offering (the “Offering Date”) they are customarily employed by the Company or a Designated
Subsidiary for more than 20 hours a week and have completed at least six months of employment. Notwithstanding any other provision herein, individuals who are not contemporaneously classified as employees of the Company or a Designated Subsidiary
for purposes of the Company’s or applicable Designated Subsidiary’s payroll system are not considered to be eligible employees of the Company or any Designated Subsidiary and shall not be eligible to participate in the Plan. In the event
any such individuals are reclassified as employees of the Company or a Designated Subsidiary for any purpose, including, without limitation, common law or statutory employees, by any action of any third party, including, without limitation, any
government agency, or as a result of any private lawsuit, action or administrative proceeding, such individuals shall, notwithstanding such reclassification, remain ineligible for participation with respect to the period before reclassification.

  

 2 

 4. Participation. 
 (a) Participants on Effective Date. Each eligible employee at the time of the Initial Public Offering shall be deemed to be a
Participant at such time. If an eligible employee is deemed to be a Participant pursuant to this Section 4(a), such individual shall be deemed not to have authorized payroll deductions and shall not purchase any Common Stock hereunder unless he
or she thereafter authorizes payroll deductions by submitting an enrollment form (in the manner described in Section 4(c)) within 30 days of the first day of the Initial Offering period. If such a Participant does not authorize payroll
deductions by submitting an enrollment form within 30 days of the first day of the Initial Offering period, that Participant will be deemed to have withdrawn from the Plan. 
 (b) Participants in Subsequent Offerings. An eligible employee who is not a Participant on any Offering Date may participate in
such Offering by submitting an enrollment form to his or her appropriate payroll location at least 15 business days before the Offering Date (or by such other deadline as shall be established by the Administrator for the Offering). 
 (c) Enrollment. The enrollment form will (a) state a whole percentage to be deducted from an eligible employee’s
Compensation (as defined in Section 11) per pay period, (b) authorize the purchase of Common Stock in each Offering in accordance with the terms of the Plan and (c) specify the exact name or names in which shares of Common Stock
purchased for such individual are to be issued pursuant to Section 10. An employee who does not enroll in accordance with these procedures will be deemed to have waived the right to participate. Unless a Participant files a new enrollment form
or withdraws from the Plan, such Participant’s deductions and purchases will continue at the same percentage of Compensation for future Offerings, provided he or she remains eligible. 
  

 3 

 (d) Notwithstanding the foregoing, participation in the Plan will neither be permitted
nor be denied contrary to the requirements of the Code. 
 5. Employee Contributions. Each eligible employee may authorize payroll
deductions at a minimum of 1 percent up to a maximum of 25 percent of such employee’s Compensation for each pay period. The Company will maintain book accounts showing the amount of payroll deductions made by each Participant for each
Offering. No interest will accrue or be paid on payroll deductions. 
 6. Deduction Changes. Except in the event of a Participant
increasing his or her payroll deduction from 0 percent during the first Offering as specified in Section 4(a) or as may be determined by the Administrator in advance of an Offering, a Participant may not increase or decrease his or her
payroll deduction during any Offering, but may increase or decrease his or her payroll deduction with respect to the next Offering (subject to the limitations of Section 5) by filing a new enrollment form at least 15 business days before the
next Offering Date (or by such other deadline as shall be established by the Administrator for the Offering). The Administrator may, in advance of any Offering, establish rules permitting a Participant to increase, decrease or terminate his or her
payroll deduction during an Offering. 
 7. Withdrawal. A Participant may withdraw from participation in the Plan by delivering a
written notice of withdrawal to his or her appropriate payroll location. The Participant’s withdrawal will be effective as of the next business day. Following a Participant’s withdrawal, the Company will promptly refund such
individual’s entire account balance under the Plan to him or her (after payment 

  

 4 

 
for any Common Stock purchased before the effective date of withdrawal). Partial withdrawals are not permitted. Such an employee may not begin participation
again during the remainder of the Offering, but may enroll in a subsequent Offering in accordance with Section 4. 
 8. Grant of
Options. On each Offering Date, the Company will grant to each eligible employee who is then a Participant in the Plan an option (“Option”) to purchase on the last day of such Offering (the “Exercise
Date”), at the Option Price hereinafter provided for, (a) a number of shares of Common Stock determined by dividing $25,000 by the Fair Market Value of the Common Stock on the Offering Date; provided, however, that such Option
shall be subject to the limitations set forth below. Each Participant’s Option shall be exercisable only to the extent of such Participant’s accumulated payroll deductions on the Exercise Date. The purchase price for each share purchased
under each Option (the “Option Price”) will be 85 percent of the Fair Market Value of the Common Stock on the Offering Date or the Exercise Date, whichever is less. 
 Notwithstanding the foregoing, no Participant may be granted an option hereunder if such Participant, immediately after the option was granted, would be
treated as owning stock possessing 5 percent or more of the total combined voting power or value of all classes of stock of the Company or any Parent or Subsidiary (as defined in Section 11). For purposes of the preceding sentence, the
attribution rules of Section 424(d) of the Code shall apply in determining the stock ownership of a Participant, and all stock which the Participant has a contractual right to purchase shall be treated as stock owned by the Participant. In
addition, no Participant may be granted an Option which permits his or her rights to purchase stock under the Plan, and any other employee stock purchase plan of the Company and its Parents and Subsidiaries, to accrue at a rate which exceeds $25,000
of the fair market value of such stock (determined on the option grant date or dates) for each calendar year in which the Option is outstanding at any time. The purpose of 

  

 5 

 
the limitation in the preceding sentence is to comply with Section 423(b)(8) of the Code and shall be applied taking Options into account in the order
in which they were granted. 
 9. Exercise of Option and Purchase of Shares. Each employee who continues to be a Participant in the
Plan on the Exercise Date shall be deemed to have exercised his or her Option on such date and shall acquire from the Company such number of whole shares of Common Stock reserved for the purpose of the Plan as his or her accumulated payroll
deductions on such date will purchase at the Option Price, subject to any other limitations contained in the Plan; provided that, with respect to the Initial Offering, the exercise of each Option shall be conditioned on the closing of the
Company’s Initial Public Offering on or before the Exercise Date. Any amount remaining in a Participant’s account at the end of an Offering solely by reason of the inability to purchase a fractional share will be carried forward to the
next Offering; any other balance remaining in a Participant’s account at the end of an Offering will be refunded to the Participant promptly. 
 10. Issuance of Certificates. Certificates representing shares of Common Stock purchased under the Plan may be issued only in the name of the employee, in the name of the employee and another person of legal age as joint tenants with
rights of survivorship, or in the name of a broker authorized by the employee to be his, her or their, nominee for such purpose. 
 11.
Definitions. 
 The term “Compensation” means the amount of total cash compensation, prior to salary reduction
pursuant to Sections 125, 132(f) or 401(k) of the Code, including base pay, overtime, commissions, and incentive or bonus awards, but excluding allowances and reimbursements for expenses such as relocation allowances or travel expenses, income
or gains on the exercise of Company stock options, and similar items. 
  

 6 

 The term “Designated Subsidiary” means any present or future Subsidiary (as
defined below) that has been designated by the Board to participate in the Plan. The Board may so designate any Subsidiary, or revoke any such designation, at any time and from time to time, either before or after the Plan is approved by the
stockholders. 
 The term “Fair Market Value of the Common Stock” on any given date means the fair market value of
the Common Stock determined in good faith by the Administrator; provided, however, that if the Common Stock is admitted to quotation on the National Association of Securities Dealers Automated Quotation System
(“NASDAQ”), NASDAQ Global Market or another national securities exchange, the determination shall be made by reference to market quotations. If there are no market quotations for such date, the determination shall be made by
reference to the last date preceding such date for which there are market quotations. Notwithstanding the foregoing, if the date for which Fair Market Value of the Common Stock is determined is the first day when trading prices for the Common Stock
are reported on NASDAQ or another national securities exchange, the Fair Market Value of the Common Stock shall be the “Price to the Public” (or equivalent) set forth on the cover page for the final prospectus relating to the
Company’s Initial Public Offering. 
 The term “Initial Public Offering” means the consummation of the first
fully underwritten, firm commitment public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, covering the offer and sale by the Company of its Common Stock. 
  

 7 

 The term “Parent” means a “parent corporation” with respect to the
Company, as defined in Section 424(e) of the Code. 
 The term “Participant” means an individual who is eligible
as determined in Section 3 and who has complied with the provisions of Section 4. 
 The term “Subsidiary”
means a “subsidiary corporation” with respect to the Company, as defined in Section 424(f) of the Code. 
 12. Rights on
Termination of Employment. If a Participant’s employment terminates for any reason before the Exercise Date for any Offering, no payroll deduction will be taken from any pay due and owing to the Participant and the balance in the
Participant’s account will be paid to such Participant or, in the case of such Participant’s death, to his or her designated beneficiary as if such Participant had withdrawn from the Plan under Section 7. An employee will be deemed to
have terminated employment, for this purpose, if the corporation that employs him or her, having been a Designated Subsidiary, ceases to be a Subsidiary, or if the employee is transferred to any corporation other than the Company or a Designated
Subsidiary. An employee will not be deemed to have terminated employment for this purpose, if the employee is on an approved leave of absence for military service or sickness or for any other purpose approved by the Company, if the employee’s
right to reemployment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Administrator otherwise provides in writing. 
 13. Special Rules. Notwithstanding anything herein to the contrary, the Administrator may adopt special rules applicable to the employees of a
particular Designated Subsidiary, whenever the Administrator determines that such rules are necessary or appropriate for the implementation of the Plan in a jurisdiction where such Designated Subsidiary has employees; provided that such rules are

  

 8 

 
consistent with the requirements of Section 423(b) of the Code. Such special rules may include (by way of example, but not by way of limitation) the
establishment of a method for employees of a given Designated Subsidiary to fund the purchase of shares other than by payroll deduction, if the payroll deduction method is prohibited by local law or is otherwise impracticable. Any special rules
established pursuant to this Section 13 shall, to the extent possible, result in the employees subject to such rules having substantially the same rights as other Participants in the Plan. 
 14. Optionees Not Stockholders. Neither the granting of an Option to a Participant nor the deductions from his or her pay shall constitute such
Participant a holder of the shares of Common Stock covered by an Option under the Plan until such shares have been purchased by and issued to him or her. 
 15. Rights Not Transferable. Rights under the Plan are not transferable by a Participant other than by will or the laws of descent and distribution, and are exercisable during the Participant’s lifetime
only by the Participant. 
 16. Application of Funds. All funds received or held by the Company under the Plan may be combined with
other corporate funds and may be used for any corporate purpose. 
 17. Adjustment in Case of Changes Affecting Common Stock. In the
event of a subdivision of outstanding shares of Common Stock, the payment of a dividend in Common Stock or any other change affecting the Common Stock, the number of shares approved for the Plan and the share limitation set forth in Section 8
shall be equitably or proportionately adjusted to give proper effect to such event. 
  

 9 

 18. Amendment of the Plan. The Board may at any time and from time to time amend the Plan in any
respect, except that without the approval within 12 months of such Board action by the stockholders, no amendment shall be made increasing the number of shares approved for the Plan or making any other change that would require stockholder approval
in order for the Plan, as amended, to qualify as an “employee stock purchase plan” under Section 423(b) of the Code. 
 19.
Insufficient Shares. If the total number of shares of Common Stock that would otherwise be purchased on any Exercise Date plus the number of shares purchased under previous Offerings under the Plan exceeds the maximum number of shares
issuable under the Plan, the shares then available shall be apportioned among Participants in proportion to the amount of payroll deductions accumulated on behalf of each Participant that would otherwise be used to purchase Common Stock on such
Exercise Date. 
 20. Termination of the Plan. The Plan may be terminated at any time by the Board. Upon termination of the Plan, all
amounts in the accounts of Participants shall be promptly refunded. 
 21. Governmental Regulations. The Company’s obligation to
sell and deliver Common Stock under the Plan is subject to obtaining all governmental approvals required in connection with the authorization, issuance, or sale of such stock. 
 22. Governing Law. This Plan and all Options and actions taken thereunder shall be governed by, and construed in accordance with, the laws of the
State of California, applied without regard to conflict of law principles. 
 23. Issuance of Shares. Shares may be issued upon
exercise of an Option from authorized but unissued Common Stock, from shares held in the treasury of the Company, or from any other proper source. 
  

 10 

 24. Tax Withholding. Participation in the Plan is subject to any minimum required tax withholding
on income of the Participant in connection with the Plan. Each Participant agrees, by entering the Plan, that the Company and its Subsidiaries shall have the right to deduct any such taxes from any payment of any kind otherwise due to the
Participant, including shares issuable under the Plan. 
 25. Notification Upon Sale of Shares. Each Participant agrees, by entering
the Plan, to give the Company prompt notice of any disposition of shares purchased under the Plan where such disposition occurs within two years after the date of grant of the Option pursuant to which such shares were purchased. 
 26. Effective Date and Approval of Stockholders. The Plan shall take effect on the date of the Company’s Initial Public Offering, subject to
approval by the holders of a majority of the votes cast at a meeting of stockholders at which a quorum is present or by written consent of the stockholders. 
  

 11Fourth Amended and Restated Registration Rights Agreement

 EXHIBIT 10.4 
 PHENOMIX CORPORATION 
 FOURTH AMENDED
AND RESTATED 
 REGISTRATION RIGHTS AGREEMENT 

THIS FOURTH AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (the “Agreement”) is made as of February 28, 2007, by and
among Phenomix Corporation, a Delaware corporation (the “Company”), Comerica Bank (“Comerica”), and the other persons listed on the attached Exhibit A to this Agreement (collectively with
Comerica, the “Investors”). 
 RECITALS 
 A. The Company and certain Investors are parties to that certain Amended and Restated Registration Rights Agreement dated as of April 14, 2005 (the
“Prior Agreement”), which Prior Agreement may be amended by the Company and by persons holding at least 70% of the then outstanding Registrable Securities as defined in Section 1 of the Prior Agreement (calculated on an
as-converted basis). 
 B. The Company and the Investors desire to enter into this Agreement in order to amend, restate and replace all
rights and obligations under the Prior Agreement. 
 C. The Company and certain of the Investors have entered into a Series C Preferred Stock
Purchase Agreement dated as of February 28, 2007 (the “Series C Purchase Agreement”) for sale by the Company and purchase by certain Investors of the Company’s Series C Preferred Stock and warrants to purchase up to
661,058 shares of Series C Preferred Stock (the “Series C Warrants”). 
 D. In order to induce the Company to enter
into the Series C Purchase Agreement and to induce the Investors to invest funds in the Company pursuant to the Series C Purchase Agreement, the Investors holding the requisite percentage of the Registrable Securities and the Company hereby agree
that this Agreement shall provide for certain registration rights of the Investors. 
 THE PARTIES AGREE AS FOLLOWS: 
 1. Certain Definitions. As used in this Agreement, the following terms shall have the following respective meanings: 
 1.1 “Commission” shall mean the Securities and Exchange Commission or any other federal agency at the time
administering the Securities Act. 
 1.2 “Exchange Act” shall mean the Securities Exchange Act of
1934, as amended. 
 1.3 “Form S-3” shall mean Form S-3 issued by the Commission or any substantially
similar form then in effect. 
  

 1.4 “Holder” shall mean any holder of outstanding Registrable
Securities which have not been sold to the public, but only if such holder is one of the Investors or an assignee or transferee of registration rights as permitted by Section 10; provided, however, that a holder of Excluded Shares
(as defined below) shall not be a Holder with respect to such Excluded Shares for purposes of Section 2.1 of this Agreement. 
 1.5 “Initiating Holders” shall mean Holders who in the aggregate hold at least 70% of the Registrable Securities. 
 1.6 “Material Adverse Event” shall mean any change, event or effect that is materially adverse to the general affairs, business, operations, assets, condition (financial or otherwise) or
results of operations of the Company and its subsidiaries taken as a whole; provided, however, that the following shall not be taken into account in determining a “Material Adverse Event”: (a) any adverse change, event or effect that
is directly attributable to conditions affecting the United States economy generally unless such conditions adversely affect the Company in a materially disproportionate manner, and (b) any adverse change, event or effect that is directly
attributable to conditions affecting the Company’s industry generally, unless such conditions adversely affect the Company in a materially disproportionate manner. 
 1.7 “Preferred Stock” shall mean the Series A4 Preferred Stock, Series A5 Preferred Stock, Series B Preferred
Stock and Series C Preferred Stock. 
 1.8 “Qualified IPO” shall mean the closing of a firm commitment
underwritten public offering pursuant to an effective Registration Statement covering the offer and sale of Common Stock for the account of the Company to the public with aggregate proceeds to the Company in excess of $50,000,000 (before deduction
for underwriters commissions and expenses) in which the valuation of the Company immediately prior to the closing of such offering is at least $200 million. 
 1.9 The terms “Register”, “Registered”, and “Registration” refer
to a registration effected by preparing and filing a registration statement on Form S-1, S-2 or S-3 in compliance with the Securities Act of 1933, as amended (“Registration Statement”), and the declaration or ordering of the
effectiveness of such Registration Statement. 
 1.10 “Registrable Securities” shall mean
(a) Common Stock of the Company issuable or issued upon conversion or exercise of any of the Preferred Stock, (b) Common Stock of the Company issued upon conversion of shares of the Company’s Series A1 Preferred Stock, Series A2
Preferred Stock and Series A3 Preferred Stock, (c) Common Stock issuable or issued upon exercise of the Warrants (the “Warrant Shares”), (d) any securities of the Company granted registration rights pursuant to
Section 9 of this Agreement and (e) any Common Stock of the Company issued as (or issuable upon conversion or exercise of any warrant, right or other security which is issued as) a dividend or other distribution with respect to, or in
exchange for or in replacement of, the shares referenced above. Notwithstanding the foregoing, Registrable Securities shall not include any securities sold by a person to the public either pursuant to a Registration Statement or Rule 144 or sold in
a transaction in which the transferor’s rights under this Agreement are not assigned in accordance with Section 10 hereof. 
  

 2 

 1.11 “Registration Expenses” shall mean all expenses incurred by
the Company in complying with Sections 2 or 3 of this Agreement, including, without limitation, all federal and state registration, qualification, and filing fees, printing expenses, fees and disbursements of counsel for the Company and one special
counsel for all Holders, blue sky fees and expenses, and the expense of any special audits incident to or required by any such registration. 
 1.12 “Securities Act” shall mean the Securities Act of 1933, as amended, or any similar federal statute, and the rules and regulations of the Commission thereunder, all as the same shall be in
effect at the time. 
 1.13 “Selling Expenses” shall mean all underwriting discounts and selling
commissions applicable to the sale of Registrable Securities pursuant to this Agreement. 
 1.14
“Warrants” shall mean (i) that certain Warrant to Purchase Stock issued by the Company to Comerica, with an Issue Date (as defined therein) as of December 23, 2004, (ii) that certain Warrant to Purchase Shares
of Series A2 Preferred Stock issued by the Company to GATX Ventures, Inc., with a Date of Grant (as defined therein) as of March 28, 2003 and (iii) the Series C Warrants. 
 2. Demand Registration. 
 2.1 Request for Registration on Form Other Than Form S-3. Subject to the terms of this Agreement, in the event that the Company shall receive from the Initiating Holders at any time after the earlier of
(a) three (3) years after the date of this Agreement or (b) 180 days after the closing of the Company’s initial public offering of shares of Common Stock under a Registration Statement, a written request that the Company effect
any Registration on a form other than Form S-3 with respect to an offering the reasonably anticipated aggregate offering price to the public of which, before deduction of Selling Expenses, would not be less than $20,000,000, the Company shall
(i) promptly give written notice of the proposed Registration to all other Holders and (ii) as soon as practicable, use its best efforts to effect Registration of the Registrable Securities specified in such request, together with any
Registrable Securities of any Holder joining in such request as are specified in a written request given within 20 days after written notice from the Company. The Company shall not be obligated to take any action to effect any such registration
pursuant to this Section 2.1 after the Company has effected three (3) such Registrations pursuant to this Section 2.1 and such Registrations have been declared effective. Notwithstanding anything in this Agreement to the contrary, the
Warrant Shares issuable upon the exercise of the Warrants described in clauses (i) and (ii) of Section 1.14, and any shares described in clause (e) of Section 1.10 that are issued in respect of such Warrant Shares
(collectively referred to as the “Excluded Shares”), shall not be Registrable Securities for purposes of this Section 2.1. 
 2.2 Request for Registration on Form S-3. If a Holder or Holders of the outstanding Registrable Securities request that the Company file a Registration Statement on Form S-3 (or any successor form to
Form S-3) for a public offering of shares of Registrable Securities the reasonably anticipated aggregate price to the public of which, before deduction of Selling Expenses, would not be less than $1,000,000, and the Company is a registrant entitled
to 

  

 3 

 
use Form S-3 to register the Registrable Securities for such an offering, the Company shall use all reasonable efforts to effect Registration of the
Registrable Securities on such form. The substantive provisions of Section 2.5 shall be applicable to each Registration initiated under this Section 2.2. If a request complying with the requirements of Section 2.2 is delivered to the
Company, the Company shall (i) promptly give written notice of the proposed Registration to all other Holders and (ii) as soon as practicable, use its best efforts to effect Registration of the Registrable Securities specified in such
request, together with any Registrable Securities of any Holder joining in such request as are specified in a written request given within 20 days after written notice from the Company. 
 2.3 Right of Deferral. Notwithstanding the foregoing, the Company shall not be obligated to file a registration statement
pursuant to this Section 2: 
 (a) if the Company, within thirty days of the receipt of the request of the Initiating
Holders, gives notice of its bona fide intention to effect the filing of a Registration Statement with the Commission for a Qualified IPO within 90 days of receipt of such request; or 
 (b) if the Company shall furnish to such Holders a certificate signed by the President of the Company stating that in the good faith
judgment of the Board of Directors it would be seriously detrimental to the Company or its stockholders for a Registration Statement to be filed in the near future, then the Company’s obligation to use all reasonable efforts to file a
Registration Statement shall be deferred for a period not to exceed 90 days from the receipt of the request to file such registration; provided, however, that the Company shall not exercise the right contained in this paragraph (b) more than
once in any 12 month period. 
 2.4 Registration of Other Securities in Demand Registration. Any Registration
Statement filed pursuant to the request of the Initiating Holders with respect to a request for Registration pursuant to Section 2.1 or the Holder or Holders requesting Registration pursuant to Section 2.2 may, subject to the provisions of
Section 2.5, include securities of the Company other than Registrable Securities. 
 2.5 Underwriting in Demand
Registration. 
 (a) Notice of Underwriting. If the Initiating Holders with respect to a request for
Registration pursuant to Section 2.1 or the Holder or Holders requesting Registration pursuant to Section 2.2 intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the
Company as a part of their request made pursuant to this Section 2, and the Company shall include such information in the written notice referred to in Section 2.1 or 2.2, as the case may be. The right of any Holder to Registration
pursuant to Section 2 shall be conditioned upon such Holder’s agreement to participate in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting. 
 (b) Inclusion of Other Holders in Demand Registration. If the Company, officers or directors of the Company holding Common
Stock other than Registrable Securities, or holders of securities other than Registrable Securities, request inclusion in a Registration pursuant to Section 2.1, the majority in interest of the Initiating Holders, to the extent they deem
advisable and consistent with the goals of such Registration, may, in their sole 

  

 4 

 
discretion, on behalf of all Holders, offer to any or all of the Company, such officers or directors, and such holders of securities other than Registrable
Securities that such securities other than Registrable Securities be included in the underwriting and may condition such offer on the acceptance by such persons of the terms of this Section 2. If, however, the number of shares so included
exceeds the number of shares of Registrable Securities included by all Holders, such Registration shall be treated as governed by Section 3 hereof rather than Section 2, and it shall not count as a Registration for purposes of
Section 2.1 hereof. 
 (c) Selection of Underwriter in Demand Registration. If the Company shall (together
with all Holders proposing to distribute their securities through such underwriting) enter into an underwriting agreement with the representative (“Underwriter’s Representative”) of the underwriter or underwriters
selected for such underwriting by the Company. The underwriter or underwriters shall be reasonably acceptable to (a) a majority in interest of the Initiating Holders in the case of a registration requested pursuant to Section 2.1 or
(b) a majority in interest of the Holder or Holders who request registration pursuant to Section 2.2. 
 (d)
Marketing Limitation in Demand Registration. If the Underwriter’s Representative advises the Initiating Holders in writing that market factors (including, without limitation, the aggregate number of shares of Common Stock
requested to be Registered, the general condition of the market, and the status of the persons proposing to sell securities pursuant to the Registration) require a limitation of the number of shares to be underwritten, then the number of shares that
may be included in the underwriting shall be allocated, (i) first, to the Holders on a pro rata basis based on the total number of Registrable Securities held by such Holders; (ii) second, to the Company; and, (iii) third, to
the officers and directors (holding securities other than Registrable Securities), and holders of securities other than Registrable Securities on a pro rata basis. No Registrable Securities or other securities excluded from the underwriting
by reason of this Section 2.5(d) shall be included in such Registration Statement. 
 (e) Right of Withdrawal in
Demand Registration. If any Holder of Registrable Securities, or a holder of other securities entitled (upon request) to be included in such Registration, disapproves of the terms of the underwriting, such person may elect to withdraw
therefrom by written notice to the Company, the Underwriter’s Representative and the Initiating Holders delivered at least seven (7) days prior to the effective date of the Registration Statement. The securities so withdrawn shall also be
withdrawn from the Registration Statement. 
 3. Piggyback Registration. 
 3.1 Notice of Piggyback Registration and Inclusion of Registrable Securities. Subject to the terms of this Agreement, if the
Company decides to Register any of its Common Stock (either for its own account or the account of a security holder or holders exercising their respective demand registration rights other than pursuant to Sections 2.1 or 2.2) on a form that would be
suitable for a registration involving solely Registrable Securities, the Company will: (a) promptly give each Holder written notice thereof (which shall include a list of the jurisdictions in which the Company intends to attempt to qualify such
securities under the 

  

 5 

 
applicable Blue Sky or other state securities laws) and (b) include in such Registration (and any related qualification under Blue Sky laws or other
compliance), and in any underwriting involved therein, all the Registrable Securities specified in a written request delivered to the Company by any Holder within 10 days after delivery of such written notice from the Company. 
 3.2 Underwriting in Piggyback Registration. 
 (a) Notice of Underwriting in Piggyback Registration. If the Registration of which the Company gives notice is for a
Registered public offering involving an underwriting, the Company shall so advise the Holders as a part of the written notice given pursuant to Section 3.1. In such event, the right of any Holder to Registration shall be conditioned upon such
underwriting and the inclusion of such Holder’s Registrable Securities in such underwriting to the extent provided in this Section 3. All Holders proposing to distribute their securities through such underwriting shall (together with the
Company and the other holders distributing their securities through such underwriting) enter into an underwriting agreement with the Underwriter’s Representative for such offering. The Holders shall have no right to participate in the selection
of the underwriters for an offering pursuant to this Section 3. 
 (b) Marketing Limitation in Piggyback
Registration. If the Underwriter’s Representative advises the Holders seeking registration of Registrable Securities pursuant to this Section 3 in writing that market factors (including, without limitation, the aggregate number of
shares of Common Stock requested to be Registered, the general condition of the market, and the status of the persons proposing to sell securities pursuant to the Registration) require a limitation of the number of shares to be underwritten, the
Underwriter’s Representative (subject to the allocation priority set forth in Section 3.2(c)) may: 
 (i) in the
case of the Company’s initial Registered public offering, exclude some or all Registrable Securities from such registration and underwriting; and 
 (ii) in the case of any Registered public offering subsequent to the initial public offering, limit the number of shares of Registrable Securities to be included in such Registration and underwriting to not less than
25% of the securities included in such Registration. 
 (c) Allocation of Shares in Piggyback Registration. If
the Underwriter’s Representative limits the number of shares to be included in a Registration pursuant to Section 3.2(b), the number of shares to be included in such Registration shall be allocated (subject to Section 3.2(b)) in the
following manner: (i) first, to the Company; (ii) second, to the Holders on a pro rata basis based on the total number of Registrable Securities held by such Holders; and (iii) third, to the officers and directors (holding
securities other than Registrable Securities), and holders of securities other than Registrable Securities on a pro rata basis. No Registrable Securities or other securities excluded from the underwriting by reason of this Section 3.2(c)
shall be included in the Registration Statement. 
 (d) Withdrawal in Piggyback Registration. If any Holder
disapproves of the terms of any such underwriting, such person may elect to withdraw therefrom by written notice to the Company and the Underwriter’s Representative delivered at least seven (7) days 

  

 6 

 
prior to the effective date of the Registration Statement. Any Registrable Securities or other securities excluded or withdrawn from such underwriting shall
be withdrawn from such Registration. 
 4. Expenses of Registration. All Registration Expenses incurred in connection with all
Registrations pursuant to Section 2.1, Section 2.2 and Section 3 shall be borne by the Company. Notwithstanding the above, the Company shall not be required to pay for any expenses of any Registration proceeding begun pursuant to
Section 2 if the Registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (which Holders shall bear such expenses), unless the Holders of a majority of the
Registrable Securities agree to forfeit their right to one demand Registration pursuant to Section 2; provided further, however, that if at the time of such withdrawal, the Holders have learned of a Material Adverse Event not known to the
Holders at the time of their request, then the Holders shall not be required to pay any of such expenses and shall retain their rights pursuant to Section 2. All Selling Expenses shall be borne by the holders of the securities Registered pro
rata on the basis of the number of shares Registered. 
 5. Termination of Registration Rights. The rights to cause the Company
to Register securities granted under Sections 2 and 3 of this Agreement and to receive notices pursuant to Section 3 of this Agreement shall terminate, with respect to each Holder, on the earlier of (a) the date five (5) years after
the closing date of the Company’s initial public offering of securities pursuant to a Registration Statement, and (b) the date all of the Registrable Securities held by such Holder and its affiliates may be sold under Rule 144 of the
Securities Act within any three (3) month period without volume limitations, without reliance on Rule 144(k) thereunder. 
 6.
Registration Procedures and Obligations. Whenever required under this Agreement to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 
 (a) Prepare and file with the Commission a Registration Statement with respect to such Registrable Securities and use its reasonable
efforts to cause such Registration Statement to become effective, and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such Registration Statement effective for up to 120 days. 
 (b) Prepare and file as expeditiously as reasonably practicable and in any event within 90 days with the Commission such amendments and
supplements to such Registration Statement and the prospectus used in connection with such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by
such Registration Statement. 
 (c) Furnish to the Holders such numbers of copies of a prospectus, including a preliminary
prospectus, in conformity with the requirements of the Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them. 
  

 7 

 (d) Use its reasonable efforts to register and qualify the securities covered by such
registration statement under such other securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the Holders, provided that the Company shall not be required in connection therewith or as a condition thereto to qualify
to do business in any jurisdiction where it is not so qualified or to file a general consent to service of process in any such states or jurisdictions, and provided further that in the event any jurisdiction in which the securities shall be
qualified imposes a non-waivable requirement that expenses incurred in connection with the qualification of the securities be borne by selling stockholders, such expenses shall be payable pro rata by selling stockholders. 
 (e) In the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the managing underwriter of such offering. Each Holder participating in such underwriting shall also enter into and perform its obligations under such an agreement. 
 (f) Notify each Holder of Registrable Securities covered by such Registration Statement at any time when a prospectus relating thereto is
required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such Registration Statement, as then in effect, includes an untrue statement of a material fact or omits to state a
material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing. 
 (g) Provide a transfer agent and registrar for all Registrable Securities registered pursuant to such Registration Statement and a CUSIP number for all such Registrable Securities, in each case not later than the
effective date of such Registration. 
 (h) Furnish, at the request of any Holder requesting Registration of Registrable
Securities pursuant to this Agreement, on the date that such Registrable Securities are delivered for sale in connection with a Registration pursuant to this Agreement, (i) an opinion, dated such date, of the counsel representing the Company
for the purposes of such Registration, in form and substance as is customarily given to underwriters (with a copy provided to each holder of Registrable Securities) in an underwritten public offering, and (ii) a letter dated such date, from the
independent certified public accountants of the Company, in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering, addressed to the underwriters (with a copy
provided to each holder of Registrable Securities). 
 (i) List the Registrable Securities covered by such Registration
Statement with any securities exchange on which the Common Stock of the Company is then listed, or such securities exchange as shall be selected by the Company. 
 (j) Notify each seller of Registrable Securities under such Registration Statement of (i) the effectiveness of such Registration
Statement, (ii) the filing of any post-effective amendments to such Registration Statement, or (iii) the filing of a supplement to such Registration Statement. 
  

 8 

 (k) Make available for inspection upon reasonable notice during the Company’s
regular business hours by each seller of Registrable Securities, any underwriter participating in any distribution pursuant to such Registration Statement, and any attorney, accountant or other agent retained by such seller or underwriter, all
material financial and other records, pertinent corporate documents and properties of the Company, and cause the Company’s officers, directors and employees to supply all information reasonably requested by any such seller, underwriter,
attorney, accountant or agent in connection with such Registration Statement. 
 7. Information Furnished by Holder. It shall
be a condition precedent of the Company’s obligations under this Agreement that each Holder of Registrable Securities included in any Registration furnish to the Company such information regarding such Holder and the distribution proposed by
such Holder or Holders as the Company may reasonably request and shall be as reasonably required in connection with any Registration. 
 8.
Indemnification. 
 8.1 Company’s Indemnification of Holders. To the extent permitted by law,
the Company will indemnify each Holder, each of its officers, directors, and constituent partners, legal counsel for the Holders, and each person controlling such Holder, with respect to which Registration, qualification, or compliance of
Registrable Securities has been effected pursuant to this Agreement, and each underwriter, if any, and each person who controls any underwriter against all claims, losses, damages, liabilities, or actions in respect thereof (collectively,
“Damages”) to the extent such Damages arise out of or are based upon any untrue statement (or alleged untrue statement) of a material fact contained in any prospectus or other document (including any related Registration
Statement) incident to any such Registration, qualification, or compliance, or are based on any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading,
or any violation by the Company of any rule or regulation promulgated under the Securities Act applicable to the Company and relating to action or inaction required of the Company in connection with any such Registration, qualification, or
compliance; and the Company will reimburse each such Holder, each such underwriter, and each person who controls any such Holder or underwriter, for any legal and any other expenses reasonably incurred in connection with investigating or defending
any such claim, loss, damage, liability, or action; provided, however, that (a) the indemnity contained in this Section 8.1 shall not apply to amounts paid in settlement of any such Damages if settlement is effected without the consent of
the Company (which consent shall not unreasonably be withheld); (b) the Company will not be liable in any such case to the extent that any such Damages arise out of or are based upon any untrue statement or omission based upon written
information furnished to the Company by such Holder, underwriter, or controlling person and stated to be specifically for use in connection with the offering of securities of the Company; and (c) the indemnity contained in this Section 8.1
is subject to the condition that, insofar as it relates to any such untrue statement (or alleged untrue statement) or omission (or alleged omission) made in a preliminary prospectus on file with the Commission at the time the Registration Statement
becomes effective or the amended prospectus is filed with the Commission pursuant to Rule 424(b) (the “Final Prospectus”), such indemnity shall not inure to the benefit of any underwriter, or any Holder, if there is no
underwriter, if a copy of the Final Prospectus was not furnished to the person asserting the claim, loss, damage, 

  

 9 

 
liability or action at or prior to the time such action is required by the Securities Act, and if the Final Prospectus would have cured the defect giving
rise to the loss, liability, claim or damage. 
 8.2 Holder’s Indemnification of Company. To the extent
permitted by law, each Holder will, if Registrable Securities held by such Holder are included in the securities as to which such Registration, qualification or, compliance is being effected pursuant to this Agreement, indemnify the Company, each of
its directors and officers, each legal counsel and independent accountant of the Company, each underwriter, if any, of the Company’s securities covered by such a Registration Statement, each person who controls the Company or such underwriter
within the meaning of the Securities Act, and each other such Holder, each of its officers, directors, and constituent partners, and each person controlling such other Holder, against all Damages arising out of or based upon any untrue statement (or
alleged untrue statement) of a material fact contained in any such Registration Statement, prospectus, offering circular, or other document, or any omission (or alleged omission) to state therein a material fact required to be stated therein or
necessary to make the statements therein not misleading, and will reimburse the Company, such Holders, such directors, officers, partners, persons, law and accounting firms, underwriters or control persons for any legal and any other expenses
reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability, or action, in each case to the extent, but only to the extent, that such untrue statement (or alleged untrue statement) or omission (or
alleged omission) is made in such Registration Statement, prospectus, offering circular, or other document in reliance upon and in conformity with written information furnished to the Company by such Holder and stated to be specifically for use in
connection with the offering of securities of the Company, provided, however, that the indemnity contained in this Section 8.2 shall not apply to amounts paid in settlement of any such Damages if settlement is effected without the consent of
such Holder (which consent shall not be unreasonably withheld) and provided, further, that each Holder’s liability under this Section 8.2 shall not exceed such Holder’s net proceeds from the offering of securities made in connection
with such Registration. 
 8.3 Indemnification Procedure. Promptly after receipt by an indemnified party under
this Section 8 of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying party under this Section 8, notify the indemnifying party in writing of the
commencement thereof and generally summarize such action. The indemnifying party shall have the right to participate in and to assume the defense of such claim; provided, however, that the indemnifying party shall be entitled to select counsel for
the defense of such claim with the approval of any parties entitled to indemnification, which approval shall not be unreasonably withheld; provided further, however, that if either party reasonably determines that there may be a conflict between the
position of the Company and the Investors in conducting the defense of such action, suit, or proceeding by reason of recognized claims for indemnity under this Section 8, then the indemnified party shall have the right to retain one separate
counsel, with the fees and expenses to be paid by the indemnifying party. The failure to notify an indemnifying party promptly of the commencement of any such action, if prejudicial to the ability of the indemnifying party to defend such action,
shall relieve such indemnifying party, to the extent so prejudiced, of any liability to the indemnified party under this Section 8, but the omission so to notify the indemnifying party will not relieve such party of any liability that such
party may have to any indemnified party otherwise than under this Section 8. 
  

 10 

 8.4 Contribution. If the indemnification provided for in this
Section 8 is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any Damages referred to therein, then the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall
contribute to the amount paid or payable by such indemnified party as a result of such Damages in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of the indemnified party on the other in
connection with the statements or omissions that resulted in such Damages as well as any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among
other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent,
knowledge, access to information, and opportunity to correct or prevent such statement or omission. 
 8.5
Conflicts. To the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions,
the provisions in the underwriting agreement shall control. Notwithstanding the foregoing, Holders shall not be obligated to enter into any underwriting agreement in connection with the exercise of Holders’ rights hereunder which includes terms
and conditions related to the Company’s or Holders’ indemnification or contribution materially less favorable to Holders than those set forth in this Agreement. 
 8.6 Survival of Obligations. The obligations of the Company and Holders under this Section 8 shall survive the
completion of any offering of Registrable Securities in a Registration Statement under this Agreement or otherwise. 
 9. Limitations
on Registration Rights Granted to Other Securities. From and after the date of this Agreement, the Company shall not enter into any agreement with any holder or prospective holder of any securities of the Company providing for the granting
to such holder of any Registration rights, except that, with the consent of the Holders of at least 70% of the Registrable Securities then outstanding, additional holders may be added as parties to this Agreement with regard to any or all securities
of the Company held by them. Any such additional parties shall execute a counterpart of this Agreement, and upon execution by such additional parties and by the Company, shall be considered an Investor for all purposes of this Agreement. The
additional parties and the additional Registrable Securities shall be identified in an amendment to Exhibit A hereto. 
 10.
Transfer of Rights. The right to cause the Company to Register securities granted by the Company to the Investors under this Agreement may be assigned by any Holder to a transferee or assignee of any Registrable Securities not sold to
the public acquiring at least 250,000 shares of Registrable Securities (equitably adjusted for any stock splits, subdivisions, stock dividends, changes, combinations or the like); provided, however, that (a) the Company must receive written
notice prior to the time of said transfer, stating the name and address of said transferee or assignee and identifying the securities with respect to which such rights are being assigned, (b) the transferee or assignee of such rights must not
be a person deemed by the Board of Directors of the Company, in its reasonable judgment, to be a competitor or potential 

  

 11 

 
competitor of the Company, and (c) such transferee or assignee must agree to be bound by the terms and conditions of this Agreement. Notwithstanding the
limitation set forth in the foregoing sentence respecting the minimum number of shares which must be transferred, (i) any Holder that is a partnership, limited liability company or corporation may transfer such Holder’s Registration rights
to (A) entities affiliated directly or indirectly with such partnership or its manager, limited liability company or corporation, (B) any partner (or retired partner or incoming partner), member (or retired member) or stockholder of such
partnership, limited liability company or corporation, (C) the spouse, siblings, lineal descendants or ancestors of any such partner (or retired partner), member (or retired member) or stockholder, (D) the estate of any such partner (or
retired partner), member (or retired member) or stockholder and (E) any custodian or trustee for the benefit of any such partner (or retired partner), member (or retired member) or stockholder or the spouse, siblings, lineal descendants or
ancestors of any such partner (or retired partner), member (or retired member) or stockholder, as the case may be, (ii) any Holder that holds shares in its capacity as trustee, manager or custodian of a trust may transfer such Holder’s
Registration rights to a replacement trustee, manager or custodian of the relevant trust, in each case, without restriction as to the number or percentage of shares acquired by any such transferee and (iii) Nomura Phase4 Ventures LP and its
affiliated funds may transfer its Registration rights to any other investment fund managed by the same manager or adviser as Nomura Phase4 Ventures LP or to any partner, participant in or manager of or adviser to Nomura Phase4 Ventures LP or such
investment fund. 
 11. Market Stand-off. Each Holder hereby agrees that, if so requested by the Company and the
Underwriter’s Representative (if any) in connection with the Company’s initial public offering, such Holder shall not sell, make any short sale of, loan, grant any option for the purchase of, or otherwise transfer or dispose of any
Registrable Securities or other securities of the Company held by such Holder immediately prior to the effective date of a Registration Statement of the Company filed under the Securities Act without the prior written consent of the Company and the
Underwriter’s Representative for such period of time (not to exceed 180 days) following the effective date of such Registration Statement as may be requested by the Underwriter’s Representative. The obligations of Holders under this
Section 11 shall be conditioned upon similar agreements being in effect with each other stockholder who is an officer, director, or 1% or greater stockholder of the Company. Any discretionary waiver or termination of the restrictions of such
agreements (including this Agreement) by the Company or Underwriter’s Representative shall apply to all persons subject to such agreements on a pro rata basis, based upon the number of shares held by each subject to such agreements. 

12. Reports Under the Exchange Act. With a view to making available to the Holders the benefits of Rule 144 promulgated under the
Securities Act and any other rule or regulation of the Commission that may at any time permit a Holder to sell securities of the Company to the public without Registration or pursuant to a registration on Form S-3, the Company agrees to: 

(a) make and keep public information available, as those terms are understood and defined in Rule 144, at all times after 90 days after
the effective date of the first Registration Statement filed by the Company for the offering of its securities to the public; 
  

 12 

 (b) take such action as is necessary to enable the Holders to utilize Form S-3 for the
sale of their Registrable Securities, such action to be taken as soon as practicable after the end of the fiscal year in which the first Registration Statement filed by the Company for the offering of its securities to the general public is declared
effective; 
 (c) file with the Commission in a timely manner all reports and other documents required of the Company under
the Securities Act and the Exchange Act; and 
 (d) furnish to any Holder, so long as the Holder owns any Registrable
Securities, promptly upon request (i) a written statement by the Company that it has complied with the reporting requirements of Rule 144 (at any time after 90 days after the effective date of the first Registration Statement filed by the
Company), the Securities Act, and the Exchange Act (at any time after it has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after it so
qualifies), (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company, and (iii) such other information as may be reasonably requested in availing any Holder of
any rule or regulation of the Commission which permits the selling of any such securities without Registration or pursuant to such form. 
 13. Miscellaneous. 
 13.1 Governing Law. This Agreement shall be governed by, and
construed in accordance with, the laws of the State of California, without giving effect to any conflicts of law provisions that would require the application of the laws of any other jurisdiction. 
 13.2 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original,
but all of which together shall constitute one and the same instrument. 
 13.3 Headings. The headings of the
Sections of this Agreement are for convenience and shall not by themselves determine the interpretation of this Agreement. 
 13.4 Notices. Any notice required or permitted hereunder shall be given in writing and shall be conclusively deemed effectively given upon personal delivery or delivery by courier, or on the first business day after
transmission if sent by confirmed facsimile transmission, or five days after deposit in the United States mail, by registered or certified mail, postage prepaid, addressed (a) if to the Company, as set forth below the Company’s name on the
signature page of this Agreement, and (b) if to an Investor, at such Investor’s address as set forth on Exhibit A, or at such other address as the Company or such Investor may designate by 10 days’ advance written notice to the
other parties hereto. 
 13.5 Amendment of Agreement. Any provision of this Agreement may be amended only by a
written instrument signed by the Company and by persons holding at least 70% of the then outstanding Registrable Securities as defined in Section 1 of this Agreement (calculated on an as-converted basis). 
  

 13 

 13.6 Severability. In case any provision of this Agreement shall be
invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. 
 13.7 Entire Agreement; Successors and Assigns. This Agreement constitutes the entire contract among the Company and the
Investors relative to the subject matter hereof. Any previous and contemporaneous agreement between the Company and any Investor concerning Registration rights is superseded by this Agreement. Subject to the exceptions specifically set forth in this
Agreement, the terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective executors, administrators, heirs, successor, and assigns of the parties. 
 13.8 Prior Agreement Superseded. Pursuant to Section 13.5 of the Prior Agreement, the undersigned parties who are parties to
the Prior Agreement hereby amend and restate the Prior Agreement to read in its entirety as set forth in this Agreement, all with the intent and effect that the Prior Agreement shall hereby be terminated and entirely replaced and superseded by this
Agreement. 
 13.9 Australian Bioscience Trust. All parties acknowledge and agree that: 
 (a) Perpetual Corporate Trust Ltd. (the “Trustee”) has entered into this Agreement only in its capacity as trustee
of the Australian Bioscience Trust (the “Trust”) and in no other capacity. A liability arising under or in connection with this Agreement is limited to and can be enforced against the Trustee only to the extent to which it
can be satisfied out of property of the Trust out of which the Trustee is actually indemnified for the liability. This limitation of the Trustee’s liability applies despite any other provision of this Agreement and extends to all liabilities
and obligations of the Trustee in any way connected with any representation, warranty, conduct, omission, agreement or transaction related to this Agreement. 
 (b) The parties, other than the Trustee, may not sue the Trustee in any capacity other than as trustee of the Trust, including seeking the
appointment of a receiver (except in relation to property of the Trust), a liquidator, an administrator or any similar person to the Trustee or prove in any liquidation, administration or arrangement of or affecting the Trustee (except in relation
to property of the Trust). 
 (c) The provisions of this Section 13.9 shall not apply to any obligation or liability of
the Trustee to the extent that it is not satisfied because under the Trust Deed establishing the Trust or by operation of law there is a reduction in the extent of the Trustee’s indemnification out of the assets of the Trust, as a result of the
Trustee’s fraud, negligence or breach of trust. 
 (d) It is acknowledged that GBS Venture Partners Limited as the
manager of the Trust is responsible under the Trust Deed establishing the Trust for performing a variety of obligations relating to the Trust, including under this Agreement. No act or omission of the Trustee (including any related failure to
satisfy its obligations or breach of representation or warranty under the Transactional Agreements (as defined in the Series C Purchase 

  

 14 

 
Agreement)) will be considered fraud, negligence or breach of trust of the Trustee for the purpose of this Section 13.9 to the extent to which the act
or omission was caused or contributed to by any failure by the manager or any other person to fulfill its obligations relating to the Trust or by any other act or omission of the manager or any other person. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 
  

 15 

 IN WITNESS WHEREOF, the parties hereto have executed this Fourth Amended and Restated Registration Rights
Agreement as of the day and year first above written. 
  

											
	Company:	 		 	PHENOMIX CORPORATION
		 		 	a Delaware corporation
				
		 		 	By:	 	/s/ Laura K. Shawver
		 		 		 		 	Laura K. Shawver, Ph.D., President
					
		 		 		 	Address:	 	 5871 Oberlin Drive
 Suite 200
 San Diego, CA 92121-3702

 SIGNATURE PAGE TO AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT 

 EXHIBIT A 
 SCHEDULE OF INVESTORS 
 Investor 
 Name and Address 
 Nomura Phase4 Ventures L.P. 
 Nomura House 
 1 St Martins-le-Grant 
 London, U.K. 
 EC1A 4NP 
 Pinnacle Ventures II-A, L.P. 
 130 Lytton Avenue, Suite 220 
 Palo Alto, CA 94301 
 Pinnacle Ventures II-B, L.P. 
 130 Lytton Avenue, Suite 220 
 Palo Alto, CA 94301 
 Pinnacle Ventures II-C, L.P. 
 130 Lytton Avenue, Suite 220 
 Palo Alto, CA 94301 
 Pinnacle Ventures II-R, L.P. 
 130 Lytton Avenue, Suite 220 
 Palo Alto, CA 94301 
 J.P. Morgan Partners (BHCA), L.P. 
 50 California Street, Suite 2940

 San Francisco, CA 94111 
 J.P. Morgan Partners Global
Investors, L.P. 
 50 California Street, Suite 2940 
 San
Francisco, CA 94111 
 J.P. Morgan Partners Global Investors (Cayman), L.P. 
 50 California Street, Suite 2940 
 San Francisco, CA 94111 
 J.P. Morgan Partners Global Investors A, L.P. 
 50 California Street, Suite 2940 
 San Francisco, CA 94111 
 J.P. Morgan Partners Global Investors (CAYMAN) II,
L.P. 
 50 California Street, Suite 2940 
 San Francisco, CA 94111

 J.P. Morgan Partners Global Investors (SELLDOWN), L.P. 
 50
California Street, Suite 2940 
 San Francisco, CA 94111 
 J.P.
Morgan Partners Global Investors (SELLDOWN) II, L.P. 
 50 California Street, Suite 2940 
 San Francisco, CA 94111 
 Delphi Ventures VI, L.P. 
 3000 Sand Hill Road 
 Building 1, Suite 135 
 Menlo Park, CA 94025 
 Delphi Bioinvestments VI, L.P. 
 3000 Sand Hill Road 
 Building 1, Suite 135 
 Menlo Park, CA 94025 

 Investor 
 Name and Address 
 Baker Bros. Investments, L.P. 
 667 Madison Avenue, 17th Floor 
 New York, NY 10021 
 Baker Bros. Investments II, L.P. 
 667 Madison Avenue, 17th Floor 
 New York, NY 10021 
 Baker/Tisch Investments, L.P. 
 667 Madison Avenue, 17th Floor 
 New York, NY 10021 
 Baker Biotech Fund I, L.P. 
 667 Madison Avenue, 17th Floor 
 New York, NY 10021 
 Baker Brothers Life Sciences, L.P. 
 667 Madison Avenue, 17th Floor 
 New York, NY 10021 
 14159, L.P. 
 667 Madison Avenue, 17th Floor 
 New York, NY 10021 
 Sofinnova Venture Partners V, L.P. 
 140 Geary Street, 10th Floor 
 San Francisco, CA 94108 
 Attn: James I. Healy 
 Sofinnova Venture Affiliates V, L.P. 
 140 Geary Street, 10th Floor 
 San Francisco, CA 94108 
 Attn: James I. Healy 
 Sofinnova Venture Principals V, L.P. 
 140 Geary Street, 10th Floor 
 San Francisco, CA 94108 
 Attn: James I. Healy 
 Alta California Partners III, L.P. 
 One Embarcadero Center, Suite 4050 
 San Francisco, CA 94111 
 Attn: Elaine Walker 
 Alta Embarcadero Partners III, LLC 
 One Embarcadero Center, Suite 4050 
 San Francisco, CA 94111 
 Attn: Elaine Walker 
 The Bay City Capital Fund III, L.P. 
 750 Battery Street 
 Suite 400 
 San Francisco, CA 94111 
 Attn: Kirby Bartlett 
 The Bay City Capital Fund III Co-Investment Fund, L.P. 
 750 Battery Street

 Suite 400 
 San Francisco, CA 94111 
 Attn: Kirby Bartlett 
  

 2 

 Investor 
 Name and Address 
 CMEA Ventures Life Sciences 2000, L.P. 
 CMEA Ventures 
 One Embarcadero Center, Suite 3250 
 San Francisco, CA 94111 
 Attn: Meryl L. Schreibstein 
 CMEA Ventures Life Sciences 2000, Civil Law Partnership 
 CMEA Ventures

 One Embarcadero Center, Suite 3250 
 San Francisco, CA 94111

 Attn: Meryl L. Schreibstein 
 Versant Venture Capital I, L.P.

 3000 Sand Hill Road 
 Building 1, Suite 260 
 Menlo Park, CA 94025 
 Versant Side Fund I, L.P. 
 3000 Sand Hill Road 
 Building 1, Suite 260 
 Menlo Park, CA 94025 
 Versant Affiliates Fund I-A, L.P. 
 3000 Sand Hill Road 
 Building 1, Suite 260 
 Menlo Park, CA 94025 
 Versant Affiliates Fund I-B, L.P. 
 3000 Sand Hill Road 
 Building 1, Suite 260 
 Menlo Park, CA 94025 
 Novartis BioVentures Ltd. 
 c/o Novartis International Pharmaceutical Ltd. 
 Hurst Holme, 12 Trott Road,

 Hamilton HM 11, Bermuda 
 Attn: Alex Hofer 
 GBS Venture Partners Limited in its capacity as Trustee of the GBS BioVentures II fund, or its nominee 
 Harley House 
 Level 5 
 71
Collins Street 
 Melbourne, VIC 3000 
 Australia 
 Perpetual Corporate Trust Ltd. in its capacity as Trustee of the Australian Bioscience Trust, or its nominee 
 Level 11 
 123 Pitt Street 
 Sydney NSW 2000 
 Coates Myer IIF Fund (or its nominee being a company or fund affiliated directly or indirectly with Coates Myer & Company
Pty Ltd or its shareholders) 
 c/o Coates Myer & Company Pty Ltd (ACN 066 426 515) 
 Level 2 
 167 Eagle Street 
 Brisbane Qld Australia 4000 
 Peter Schultz 
 1650 La
Jolla Rancho Road 
 La Jolla, CA 92037 
  

 3 

 Investor 
 Name and Address 
 Isy Goldwasser, Trustee of the Amangani Trust UDT dated July 19, 2001 
 580 Arastradero Road, #505 
 Palo Alto, CA 94306-3947 
 Richard Lerner and Nicola G. Lerner, Trustees or Successor Trustee, of the Lerner Family Trust U/A/D 11/14/94 
 7750 East Roseland Drive 
 La Jolla, CA 92037-4015 
 Trefoil S.A. 
 Cay House 
 PO Box N7776, Lyford Cay 
 New Providence, Bahamas 
 Attn: Joseph C. Lewis 
 The Australian National University 
 Acton, ACT 0200 
 Australia 
 Attn: Investment Manager 
 HEWM/VLG Investments, LLC 
 275 Middlefield Road Menlo Park, CA 94025 
 Attn: Mark A. Royer, Fund Manager

 City National Bank, Trustee Heller Ehrman White & McAuliffe (HEWM) MPP/PSP FBO Stephen Ferruolo 
 225 Broadway, Fifth Floor 
 San Diego, CA 92101 
 Attn: Mary Jo Topp 
 Allan Bradley 
 Wellcome Trust Genome Campus 
 Hinxton, England, UK CB 101 SA 
 IRM LLC 
 c/o Novartis International 
 Pharmaceutical Ltd. 
 Hurst Holme, 12 Trott Road 
 Hamilton HM 11 
 Bermuda 
 The Denise M. Gilbert Revocable Trust 
 5 Woodfern 
 Portola Valley, CA 94028 
  

 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00135-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00135-of-00352.parquet"}]]